These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 25282488

  • 1. [Current management of thalassemia intermedia].
    Thuret I.
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [Abstract] [Full Text] [Related]

  • 2. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
    Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J.
    Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
    [Abstract] [Full Text] [Related]

  • 3. Thalassemia intermedia: revisited.
    Taher A, Isma'eel H, Cappellini MD.
    Blood Cells Mol Dis; 2006 Jul; 37(1):12-20. PubMed ID: 16737833
    [Abstract] [Full Text] [Related]

  • 4. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD, Motta I.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):278-283. PubMed ID: 29222267
    [Abstract] [Full Text] [Related]

  • 5. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E.
    Haematologica; 2007 May 08; 92(5):583-8. PubMed ID: 17488680
    [Abstract] [Full Text] [Related]

  • 6. β-thalassemia intermedia: a clinical perspective.
    Musallam KM, Taher AT, Rachmilewitz EA.
    Cold Spring Harb Perspect Med; 2012 Jul 08; 2(7):a013482. PubMed ID: 22762026
    [Abstract] [Full Text] [Related]

  • 7. β- and α-Thalassemia intermedia in Basra, Southern Iraq.
    Abdulwahid DA, Hassan MK.
    Hemoglobin; 2013 Jul 08; 37(6):553-63. PubMed ID: 23944608
    [Abstract] [Full Text] [Related]

  • 8. Thalassemia Intermedia: Chelator or Not?
    Lee YC, Yen CT, Lee YL, Chen RJ.
    Int J Mol Sci; 2022 Sep 05; 23(17):. PubMed ID: 36077584
    [Abstract] [Full Text] [Related]

  • 9. Insight onto the pathophysiology and clinical complications of thalassemia intermedia.
    Cappellini MD, Musallam KM, Taher AT.
    Hemoglobin; 2009 Sep 05; 33 Suppl 1():S145-59. PubMed ID: 20001620
    [Abstract] [Full Text] [Related]

  • 10. Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia.
    Aessopos A, Tassiopoulos S, Farmakis D, Moyssakis I, Kati M, Polonifi K, Tsironi M.
    Ann Thorac Surg; 2006 Jun 05; 81(6):2037-43. PubMed ID: 16731126
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis.
    Cario H, Wegener M, Debatin KM, Kohne E.
    Ann Hematol; 2002 Aug 05; 81(8):478-82. PubMed ID: 12224008
    [Abstract] [Full Text] [Related]

  • 13. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN, Taher AT.
    Ann N Y Acad Sci; 2016 Mar 05; 1368(1):82-94. PubMed ID: 27186941
    [Abstract] [Full Text] [Related]

  • 14. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A, El-Ghamrawy M, EL-Ela MA, Said F, Adolf S, Abdel-Razek AR, Magdy RI, Abdel-Salam A.
    Ann Hematol; 2014 Dec 05; 93(12):2045-50. PubMed ID: 25062719
    [Abstract] [Full Text] [Related]

  • 15. Beta-thalassemia.
    Rund D, Rachmilewitz E.
    N Engl J Med; 2005 Sep 15; 353(11):1135-46. PubMed ID: 16162884
    [No Abstract] [Full Text] [Related]

  • 16. [Overview of new approaches to β-thalassemia treatment].
    Guo XF, Han L, Zhang XC, Zhang HH, Liu J.
    Sheng Li Xue Bao; 2024 Jun 25; 76(3):496-506. PubMed ID: 38939943
    [Abstract] [Full Text] [Related]

  • 17. An update on thalassemia intermedia.
    Maakaron JE, Cappellini MD, Taher AT.
    J Med Liban; 2013 Jun 25; 61(3):175-82. PubMed ID: 24422369
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Guidelines for diagnosis and management of Beta-thalassemia intermedia.
    Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A.
    Pediatr Hematol Oncol; 2014 Oct 25; 31(7):583-96. PubMed ID: 25247665
    [Abstract] [Full Text] [Related]

  • 20. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.
    Eur J Haematol; 2010 Jan 01; 84(1):72-8. PubMed ID: 19732137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.